Last reviewed · How we verify
Icodextrin PD solution
At a glance
| Generic name | Icodextrin PD solution |
|---|---|
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. (PHASE3)
- Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients
- Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients (PHASE4)
- Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine (PHASE2)
- Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients (PHASE1)
- Incremental PD With Single Icodextrin Exchange (NA)
- Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD (PHASE2)
- Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Icodextrin PD solution CI brief — competitive landscape report
- Icodextrin PD solution updates RSS · CI watch RSS
- Yonsei University portfolio CI